<DOC>
	<DOCNO>NCT01120561</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm , expand access study design provide T-DM1 patient HER2-positive locally advanced metastatic breast cancer evaluate safety efficacy T-DM1 administer intravenous ( IV ) infusion .</brief_summary>
	<brief_title>A Study Trastuzumab-MCC-DM1 Patients With HER2- Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically cytologically document breast cancer Locally advance metastatic breast cancer HER2positive breast cancer document FISHpositive , IHC 3 + CISHpositive local laboratory assessment Histologically cytologically confirm invasive breast cancer : incurable , unresectable , locally advanced breast cancer previously treat multimodality therapy metastatic breast cancer Prior treatment breast cancer adjuvant , unresectable , locally advanced , metastatic setting must include : taxane , alone combination another agent , Trastuzumab , alone combination another agent adjuvant , unresectable , locally advanced , metastatic setting Documented progression incurable unresectable , locally advanced , metastatic breast cancer recent treatment regimen Progression must occur recent treatment locally advanced/metastatic breast cancer within 6 month complete adjuvant therapy Adequate hematologic end organ function Agreement use effective form birth control throughout study Life expectancy ≥ 90 day assess investigator Less 14 day first study treatment since last anticancer therapy , include chemotherapy , biologic , experimental , immune , hormonal endocrine therapy Prior TDM1 therapy History exposure cumulative dos select anthracyclines History intolerance hypersensitivity trastuzumab , murine protein , excipients , result trastuzumab permanently discontinue Brain metastasis untreated progressive currently require type therapy , include radiation , surgery , and/or steroid control symptoms brain metastasis within 30 day first study treatment Peripheral neuropathy Grade ≥ 3 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) , version 4.0 , time first study treatment History clinically significant cardiac dysfunction Current know active infection HIV , hepatitis B virus , hepatitis C virus Current severe , uncontrolled systemic disease Major surgical procedure significant traumatic injury within 28 day prior first study treatment Pregnancy lactation NOTE : The site selection process complete . Patients enroll participate site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TDM-1 EAP</keyword>
	<keyword>T-DM1 EAP</keyword>
	<keyword>TDM1 EAP</keyword>
	<keyword>Trastuzumab-MCC-DM1 EAP</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>EAP</keyword>
	<keyword>T-PAS</keyword>
</DOC>